Zestama

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Zestama
Generic name: CAPSAICIN
Manufacturer: V2 Pharma LLC
Product type: HUMAN OTC DRUG
SPL set ID: c9b46759-b8df-4ff4-815e-8e032c2635c0
SPL ID: 02d2eede-eb2b-448b-b9b3-0fe4387561fd
Version: 5
Effective date: 2025-12-15
Source export date: 2026-11-06
Source partition: 9
Source file: https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-11-06/5731a8c92e1c0dd2a09d2f92b410e7a70ea29cbf6b8040a6a05e4be5b7c51f0d/drug-label-0009-of-0014.json.zip
Source manifest SHA-256: 4a7570ba105b5a039a8e1c94a85e7f085b9047a8882a35a96bf1e4516c5ffc97
Import run: 20261108T063105Z
Imported at: 2026-11-08 07:44:56

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M017	openfda.application_number
brand name		Zestama	openfda.brand_name
generic name		CAPSAICIN	openfda.generic_name
manufacturer name		V2 Pharma LLC	openfda.manufacturer_name
ndc	package	72835-175-01	openfda.package_ndc
ndc	product	72835-175	openfda.product_ndc
ndc11	package	72835017501	derived:openfda.package_ndc
rxcui		358922	openfda.rxcui
spl id		02d2eede-eb2b-448b-b9b3-0fe4387561fd	id
spl set id		c9b46759-b8df-4ff4-815e-8e032c2635c0	set_id
unii		S07O44R1ZM	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Fore external use only Read all warnings and directions before use. Test first on small area of skin. When using this product you may experience a burning sensation and/or skin redness. The intensity of this reaction varies among individuals and may be severe. With regular use, this generally disappears after several days.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.